TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04522336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Receive radiation therapy
Study: NCT02281110

Intervention type: DEVICE
Intervention: iFR/FFR
Description: • The Volcano iFR®-FFR option, which is a measurement modality for the Volcano system that provides the capability to make FFR and instantaneous wave-Free Ratio™ (iFR®) measurements (CE-Marked). iFR® is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option. This PIM-FFR is compatible with all Volcano pressure measurement guide wires.
Study: NCT01304069

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will be given orally placebo twice a day for 7 days prior to the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selecoxib
Description: The subjects will be given orally selecoxib 200mg twice a day for 7 days prior to the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: The subjects will be given orally etoricoxib 120mg once a day for 7 days prior to the study.
Study: NCT03978637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib administered orally at the specified dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib administered orally at the specified dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib administered orally at the specified dose.
Study: NCT04434651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPGB
Description: Sphenopalatine Ganglion Block using 2% lidocaine in block group. Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge a syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril SPGB using normal saline is performed in the control group
Study: NCT00083603

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)
Description: Vaccines administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)
Description: Vaccines administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)
Description: Vaccines administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)
Description: Vaccines administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid
Study: NCT03369392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Panda application
Description: A smartphone-based postoperative pain management tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Panda application
Description: A smartphone-based postoperative pain management tool
Study: NCT03978637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib administered orally at the specified dose.
Study: NCT05929118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Rehabilitation
Description: Reviewing the existing literature studies and related books, and combining the post-operative rehabilitation process of ACLR with the opinions of experts from the China Aquatic Rehabilitation Association, the Aquatic rehabilitation program of this study was designed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Land-based Rehabilitation
Description: Peking University Third Hospital Anterior Cruciate Ligament (ACL) Postoperative Rehabilitation Guidelines.
Study: NCT03369392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Panda application
Description: A smartphone-based postoperative pain management tool
Study: NCT04434651

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SPGB
Description: Sphenopalatine Ganglion Block using 2% lidocaine in block group. Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge a syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril SPGB using normal saline is performed in the control group
Study: NCT01690624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836858
Description: Monotherapy with BI 836858 administered as intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836858
Description: Monotherapy with BI 836858 administered as intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836858
Description: Monotherapy with BI 836858 administered as intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836858
Description: Monotherapy with BI 836858 administered as intravenous infusion
Study: NCT03048968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gait, sit-to-stand movement, stair climbing and treadmill gait
Description: Spatio temporal characteristics, muscle activation and foot pressure distribution are measured by motion capture system, surface electromyography (sEMG) and F-Scan Mobile system during 10m walking test. Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test.Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during stair climbing. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
Study: NCT01950390

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study: NCT03048968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sit-to-stand movement and treadmill gait
Description: Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gait enhancing mechatronic system (GEMS)
Description: Gait, sit-to-stand movement, stair climbing and treadmill gait with GEMS and without GEMS in elderly adults.~Sit-to-stand movement and treadmill gait with GEMS and without GEMS in stroke patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gait enhancing mechatronic system (GEMS)
Description: Gait, sit-to-stand movement, stair climbing and treadmill gait with GEMS and without GEMS in elderly adults.~Sit-to-stand movement and treadmill gait with GEMS and without GEMS in stroke patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Description: Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Description: Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
Study: NCT00136656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic
Description: cephalosporine by oral route : cefixime

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: antibiotics
Description: cephalosporine : ceftriaxone by intra venous route and cefixime by oral route
Study: NCT03829982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to bright light during the day
Description: Participants will be exposed to bright light (1250 lux) between 8:00 and 18:00 and to dim light (5 lux) between 18:00 and 23:00.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to dim light during the day
Description: Participants will be exposed to dim light (10 lux) between 8:00 and 18:00 and to dim light (1250 lux) between 18:00 and 23:00.
Study: NCT03893799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-1
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-1
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-1
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-1
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-1
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-1
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-1
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-1
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-1
Description: intravenous administration
Study: NCT04006613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit Training
Description: 20 minutes of High Intensity Aerobic Training (HI) on treadmill: 2 minutes warm up + 4x 4 minutes HI+ 2 minutes of active recovery; 10 minutes of dynamic balance training; 10 minutes of functional strength training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Exercises aimed at improving mobility and balance
Study: NCT03158415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T1DToolkit.org mobile diabetes education
Description: Participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.~Six weeks after enrollment, participants will complete the Modified Diabetes Distress Scale: Parents of Young Adults.
Study: NCT00527267

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 mg placebo once daily orally 60 mg placebo once daily orally 90 mg placebo once daily orally 120 mg placebo once daily orally 180 mg placebo once daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 073
Description: 30 mg AMG 073 once daily 60 mg AMG 073 once daily 90 mg AMG 073 once daily 120 mg AMG 073 once daily 180 mg AMG 073 once daily
Study: NCT02674841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback on TUT
Description: Access to live visual and auditory feedback on TUT and pulling force from an application on an iPad.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No feedback on TUT
Description: Access only to live visual feedback on pulling force from an application on an iPad.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 3 exercises (knee extension, hip abduction and hip extension) using an elastic band with 3 sets of 10 repetitions at 10-12 RM 3 times a week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 3 exercises (knee extension, hip abduction and hip extension) using an elastic band with 3 sets of 10 repetitions at 10-12 RM 3 times a week for 6 weeks.
Study: NCT02235298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 5 mg taken orally once daily. After 2 weeks, if there are no safety issues as per treating physician discretion, the dose can be titrated up to 10 mg orally taken once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo pill taken once daily to mimic Dapagliflozin
Study: NCT00485693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: 150 mg Bupivacaine HCl

Intervention type: DRUG
Group type: OTHER
Intervention: SKY0402
Description: 600 mg SKY0402 (study drug)
Study: NCT03565484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: susceptibility guided therapy
Description: Patients will take a gastroscopy and 2 biopsies will be attained from antrum and gastric body for H.pylori culture and antimicrobial susceptibility testing (AST). The susceptibility of amoxicillin, clarithromycin, metronidazole, levofloxacin, furazolidone and tetracycline will be tested.Then patients with positive culture will be treated with a 14-day quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, and two sensitive antibiotics determined by AST. Dose of two sensitive antibiotics are listed as follows : amoxicillin 1000mg bid, clarithromycin 500mg bid, tinidazole 500mg tid, levofloxacin 500mg qd, furazolidone 100mg bid, tetracycline 500mg qid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: personal medication history guided therapy
Description: Patients will be treated with a 14-day emprical tailored quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid， colloidal bismuth pectin 200mg bid and two antibiotics based on personal medication history. If the patient doesn't have levofloxacin history, he will be treated with amoxicillin 1000mg bid plus levofloxacin 500mg bid. Otherwise, he will be treated with amoxicillin 1000mg bid and furazolidone 100mg bid.

Intervention type: DRUG
Group type: OTHER
Intervention: personal medication history guided therapy
Description: Patients will be treated with a 14-day emprical tailored quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid， colloidal bismuth pectin 200mg bid and two antibiotics based on personal medication history. If the patient doesn't have levofloxacin history, he will be treated with amoxicillin 1000mg bid plus levofloxacin 500mg bid. Otherwise, he will be treated with amoxicillin 1000mg bid and furazolidone 100mg bid.

Intervention type: DRUG
Group type: OTHER
Intervention: salvage treatment for failed eradication
Description: If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, tetracycline 500mg qid and furazolidone 100mg bid.
Study: NCT01565187

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Transplant Effects Questionnaire, Response Evaluation Measure, Patient Health Questionnaire, Generalized Anxiety Scale, Alcohol Use Disorders Test, Body Image Questionnaire, Quality of Life Uniscale, Scales of Psychosocial Well-Being, Sense of Coherence Scale.
Study: NCT00973999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin
Description: Each parotid salivary gland will be injected with 75MU of Botulinum Toxin type-A, 0.15mls in total, with 0.09mls into the mass of the gland and another 0.06mls into the adjacent part above the masseter muscle, using a 1ml syringe and a 30 gauge needle.~Each submandibular salivary gland will be injected with 15MU of Botulinum Toxin A, administering 0.03mls, using a 1ml syringe and a 30 gauge needle.
Study: NCT04452383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine + propofol
Description: effect of adding ketamine to propofol for patients undergoing DISE surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: effect of IV propofol alone for patients undergoing DISE surgery
Study: NCT03874169

Intervention type: DEVICE
Intervention: E4 wristband
Description: A biosensor watch that monitors the patient's heartbeat, heart rate variability, skin conductance, and temperature in order to discover if they are having a GI bleed
Study: NCT01878305

Intervention type: DEVICE
Intervention: Molecular Adsorbent Recirculating System (MARS)
Description: MARS is an extracorporeal albumin dialysis device, used in the treatment of liver failure patients to stabilize the patient and halt the progression of HE, giving the liver time to recover in some cases and allowing additional time before liver transplantation in others.
Study: NCT03303534

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ScandiShake
Description: weight gain supplement low in protein
Study: NCT01911871

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: a blood sample was taken on the day of inclusion
Study: NCT00012259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: troxacitabine
Study: NCT02842957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Patients randomized to the lifestyle group will be given individual counseling regarding the implementation of a plant based diet. They will also be given a home based exercise program to complete. Patients will be assisted with the optimal use of their prescription medications and they will receive specific counseling regarding strategies to help them successfully change their behavior.
Study: NCT00758550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® Toric IOL
Description: AcrySof® Toric Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AcrySof Natural
Description: AcrySof Natural Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
Study: NCT00968695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: The pattern of administration of 20% human albumin is 1.5g/kg every week to be infused in 6 hours with a minimum of 90g up and a maximum of 150g in patients weighing less than 60 kg and more than 100 kg, respectively. Treatment duration is 12 weeks, which are 13 administrations of albumin.
Study: NCT01588093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Increlex
Description: Increlex 120 micrograms/kg body weight single subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo (0,1 ml of 0.9% Saline) single subcutaneous injection
Study: NCT00869934

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavior Therapy
Description: Sleep restriction, stimulus control, cognitive therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavior Therapy
Description: Sleep restriction and stimulus control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: Cognitive restructuring therapy
Study: NCT01830049

Intervention type: OTHER
Intervention: Take blood

Intervention type: OTHER
Intervention: Take blood

Intervention type: OTHER
Intervention: Take blood
Study: NCT03188835

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Diet
Description: A 2 weeks of hypercaloric diet supplemented with fructose or glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Diet
Description: A 2 weeks of hypercaloric diet supplemented with fructose or glucose

Intervention type: OTHER
Group type: OTHER
Intervention: cold exposure
Description: Acute cold exposure using a water-conditioned cooling suit will be applied from time 0 to 180 min. At the same time mean skin temperature will be measured by 11 thermocouples.
Study: NCT01911871

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: a blood sample was taken on the day of inclusion

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: a blood sample was taken on the day of inclusion
Study: NCT00859404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oglemilast
Description: Tablet oglemilast or placebo once a day, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oglemilast
Description: Tablet oglemilast or placebo once a day, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oglemilast
Description: Tablet oglemilast or placebo once a day, for 12 weeks
Study: NCT03188835

Intervention type: OTHER
Group type: OTHER
Intervention: cold exposure
Description: Acute cold exposure using a water-conditioned cooling suit will be applied from time 0 to 180 min. At the same time mean skin temperature will be measured by 11 thermocouples.

Intervention type: OTHER
Group type: OTHER
Intervention: cold exposure
Description: Acute cold exposure using a water-conditioned cooling suit will be applied from time 0 to 180 min. At the same time mean skin temperature will be measured by 11 thermocouples.
Study: NCT00083603

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)
Description: Vaccines administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)
Description: Vaccines administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid